The 22q13.3 deletion syndrome, also known as Phelan-McDermid syndrome, is a contiguous gene disorder resulting from deletion of the distal long arm of chromosome 22. In addition to normal growth and a constellation of minor dysmorphic features, this syndrome is characterized by neurological deficits which include global developmental delay, moderate to severe intellectual impairment, absent or severely delayed speech, and neonatal hypotonia. In addition, more than 50% of patients show autism or autistic-like behavior, and therefore it can be classified as a syndromic form of autism spectrum disorders (ASD). The differential diagnosis includes Angelman syndrome, velocardiofacial syndrome, fragile X syndrome, and FG syndrome. Over 600 cases of 22q13.3 deletion syndrome have been documented. Most are terminal deletions of ∼100 kb to >9 Mb, resulting from simple deletions, ring chromosomes, and unbalanced translocations. Almost all of these deletions include the gene SHANK3 which encodes a scaffold protein in the postsynaptic densities of excitatory synapses, connecting membrane-bound receptors to the actin cytoskeleton. Two mouse knockout models and cell culture experiments show that SHANK3 is involved in the structure and function of synapses and support the hypothesis that the majority of 22q13.3 deletion syndrome neurological defects are due to haploinsufficiency of SHANK3, although other genes in the region may also play a role in the syndrome. The molecular connection to ASD suggests that potential future treatments may involve modulation of metabotropic glutamate receptors.

Keywords:
SHANK3, 22q13.3 deletion syndrome, Autism spectrum disorders
1.
Anderlid BM, Schoumans J, Anneren G, Tapia-Paez I, Dumanski J, et al: FISH-mapping of a 100-kb terminal 22q13 deletion. Hum Genet 110:439–443 (2002).
2.
Barakat AJ, Pearl PL, Acosta MT, Runkle BP: 22q13 deletion syndrome with central diabetes insipidus: a previously unreported association. Clin Dysmorphol 13:191–194 (2004).
3.
Bartsch O, Schneider E, Damatova N, Weis R, Tufano M, et al: Fulminant hepatic failure requiring liver transplantation in 22q13.3 deletion syndrome. Am J Med Genet A 152A:2099–2102 (2010).
4.
Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370–377 (2004).
5.
Benedict C, Hallschmid M, Schultes B, Born J, Kern W: Intranasal insulin to improve memory function in humans. Neuroendocrinology 86:136–142 (2007).
6.
Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, et al: Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42:489–491 (2010).
7.
Bisgaard AM, Kirchhoff M, Nielsen JE, Kibaek M, Lund A, et al: Chromosomal deletion unmasking a recessive disease: 22q13 deletion syndrome and metachromatic leukodystrophy. Clin Genet 75:175–179 (2009).
8.
Böckers TM, Bockmann J, Kreutz MR, Gundelfinger ED: ProSAP/Shank proteins – a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81:903–910 (2002).
9.
Böckers TM, Segger-Junius M, Iglauer P, Bockmann J, Gundelfinger ED, et al: Differential expression and dendritic transcript localization of Shank family members: identification of a dendritic targeting element in the 3′ untranslated region of Shank1 mRNA. Mol Cell Neurosci 26:182–190 (2004).
10.
Bockmann J, Kreutz MR, Gundelfinger ED, Bockers TM: ProSAP/Shank postsynaptic density proteins interact with insulin receptor tyrosine kinase substrate IRSp53. J Neurochem 83:1013–1017 (2002).
11.
Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, et al: Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 69:261–268 (2001).
12.
Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, et al: Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 43:822–828 (2006).
13.
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL: Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516 (2002).
14.
Bourgeron T: A synaptic trek to autism. Curr Opin Neurobiol 19:231–234 (2009).
15.
Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, et al: Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 1:15 (2010).
16.
Chen C, Xiao SF: Induced pluripotent stem cells and neurodegenerative diseases. Neurosci Bull 27:107–114 (2011).
17.
Cody JD, Pierce JF, Brkanac Z, Plaetke R, Ghidoni PD, et al: Preferential loss of the paternal alleles in the 18q-syndrome. Am J Med Genet 69:280–286 (1997).
18.
Cusmano-Ozog K, Manning MA, Hoyme HE: 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. Am J Med Genet C Semin Med Genet 145C:393–398 (2007).
19.
Delahaye A, Toutain A, Aboura A, Dupont C, Tabet AC, et al: Chromosome 22q13.3 deletion syndrome with a de novo interstitial 22q13.3 cryptic deletion disrupting SHANK3. Eur J Med Genet 52:328–332 (2009).
20.
Dhar SU, del Gaudio D, German JR, Peters SU, Ou Z, et al: 22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A 152A:573–581 (2010).
21.
D’Hulst C, Kooy RF: The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 30:425–431 (2007).
22.
Doheny KF, McDermid HE, Harum K, Thomas GH, Raymond GV: Cryptic terminal rearrangement of chromosome 22q13.32 detected by FISH in two unrelated patients. J Med Genet 34:640–644 (1997).
23.
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, et al: Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39:25–27 (2007).
24.
Flint J, Wilkie AO, Buckle VJ, Winter RM, Holland AJ, McDermid HE: The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nat Genet 9:132–140 (1995).
25.
Gauthier J, Spiegelman D, Piton A, Lafreniere RG, Laurent S, et al: Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B:421–424 (2009).
26.
Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, et al: De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA 107:7863–7868 (2010).
27.
Giza J, Urbanski MJ, Prestori F, Bandyopadhyay B, Yam A, et al: Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2. J Neurosci 30:14805–14816 (2010).
28.
Goizet C, Excoffier E, Taine L, Taupiac E, El Moneim AA, et al: Case with autistic syndrome and chromosome 22q13.3 deletion detected by FISH. Am J Med Genet 96:839–844 (2000).
29.
Herman GE, Greenberg F, Ledbetter DH: Multiple congenital anomaly/mental retardation (MCA/MR) syndrome with Goldenhar complex due to a terminal del(22q). Am J Med Genet 29:909–915 (1988).
30.
Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, et al: Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 28:1697–1708 (2008).
31.
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, et al: Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34:27–29 (2003).
32.
Katz RT: Life expectancy for children with cerebral palsy and mental retardation: implications for life care planning. NeuroRehabilitation 18:261–270 (2003).
33.
Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, et al: Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 82:199–207 (2008).
34.
Kirkpatrick BE, El-Khechen D: A unique presentation of 22q13 deletion syndrome: multicystic kidney, orofacial clefting, and Wilms’ tumor. Clin Dysmorphol 20:53–54 (2011).
35.
Kirshenbaum G, Chmura M, Rhone DP: Long arm deletion of chromosome 22. J Med Genet 25:780 (1988).
36.
Klemm U, Muller-Esterl W, Engel W: Acrosin, the peculiar sperm-specific serine protease. Hum Genet 87:635–641 (1991).
37.
Kolevzon A, Cai G, Soorya L, Takahashi N, Grodberg D, et al: Analysis of a purported SHANK3 mutation in a boy with autism: clinical impact of rare variant research in neurodevelopmental disabilities. Brain Res 1380:98–105 (2011).
38.
Koolen DA, Reardon W, Rosser EM, Lacombe D, Hurst JA, et al: Molecular characterisation of patients with subtelomeric 22q abnormalities using chromosome specific array-based comparative genomic hybridisation. Eur J Hum Genet 13:1019–1024 (2005).
39.
Kramer M, Backhaus O, Rosenstiel P, Horn D, Klopocki E, et al: Analysis of relative gene dosage and expression differences of the paralogs RABL2A and RABL2B by pyrosequencing. Gene 455:1–7 (2010).
40.
Kreienkamp HJ: Scaffolding proteins at the postsynaptic density: Shank as the architectural framework. Handb Exp Pharmacol 186:365–380 (2008).
41.
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, et al: X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 74:552–557 (2004).
42.
Liu LM, Zhang JX, Wang XP, Guo HX, Deng H, Luo J: Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats. Eur J Clin Invest 40:127–138 (2010).
43.
Luciani JJ, de Mas P, Depetris D, Mignon-Ravix C, Bottani A, et al: Telomeric 22q13 deletions resulting from rings, simple deletions, and translocations: cytogenetic, molecular, and clinical analyses of 32 new observations. J Med Genet 40:690–696 (2003).
44.
Mainardi PC, Perfumo C, Cali A, Coucourde G, Pastore G, et al: Clinical and molecular characterisation of 80 patients with 5p deletion: genotype-phenotype correlation. J Med Genet 38:151–158 (2001).
45.
Manning MA, Cassidy SB, Clericuzio C, Cherry AM, Schwartz S, et al: Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 114:451–457 (2004).
46.
Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D’Souza C, et al: Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466:253–257 (2010).
47.
McGaughran J, Hadwen T, Clark R: Progressive edema leading to pleural effusions in a female with a ring chromosome 22 leading to a 22q13 deletion. Clin Dysmorphol 19:28–29 (2010).
48.
Micale MA, Haren JM, Conroy JM, Crowe CA, Schwartz S: Parental origin of de novo chromosome 9 deletions in del(9p) syndrome. Am J Med Genet 57:79–81 (1995).
49.
Misceo D, Rodningen OK, Baroy T, Sorte H, Mellembakken JR, et al: A translocation between Xq21.33 and 22q13.33 causes an intragenic SHANK3 deletion in a woman with Phelan-McDermid syndrome and hypergonadotropic hypogonadism. Am J Med Genet A 155:403–408 (2011).
50.
Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, et al: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289–1297 (2007).
51.
Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, et al: Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23:569–582 (1999).
52.
Narahara K, Takahashi Y, Murakami M, Tsuji K, Yokoyama Y, et al: Terminal 22q deletion associated with a partial deficiency of arylsulphatase A. J Med Genet 29:432–433 (1992).
53.
Nesslinger NJ, Gorski JL, Kurczynski TW, Shapira SK, Siegel-Bartelt J, et al: Clinical, cytogenetic, and molecular characterization of seven patients with deletions of chromosome 22q13.3. Am J Hum Genet 54:464–472 (1994).
54.
Pasini A, D’Agati E, Casarelli L, Curatolo P: Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome. Brain Dev 32:425–427 (2010).
55.
Peca J, Feliciano C, Ting JT, Wang W, Wells MF, et al: Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472:437–442 (2011).
56.
Phelan K: 22q13.3 deletion syndrome; in Pagon RA, Bird TD, Dolan CR, Stephens K (eds): GeneTests: GeneReviews [Internet], (University of Washington, Seattle, WA 2007). Available at http://www.ncbi.nlm.nih.gov/books/NBK1198/.
57.
Phelan K, Betancur C: Clinical utility gene card for: deletion 22q13 syndrome. Eur J Hum Genet 19 (2011).
58.
Phelan MC, Rogers RC, Stevenson RE: A de novo terminal deletion of 22q. Am J Hum Genet 43:A118 (1988).
59.
Phelan MC, Thomas GR, Saul RA, Rogers RC, Taylor HA, et al: Cytogenetic, biochemical, and molecular analyses of a 22q13 deletion. Am J Med Genet 43:872–876 (1992).
60.
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, et al: 22q13 deletion syndrome. Am J Med Genet 101:91–99 (2001).
61.
Phelan MC, Stapleton GA, Rogers RC: The Management of Genetic Syndromes (Wiley-Liss, Inc., Hoboken 2010).
62.
Prasad C, Prasad AN, Chodirker BN, Lee C, Dawson AK, et al: Genetic evaluation of pervasive developmental disorders: the terminal 22q13 deletion syndrome may represent a recognizable phenotype. Clin Genet 57:103–109 (2000).
63.
Precht KS, Lese CM, Spiro RP, Huttenlocher PR, Johnston KM, et al: Two 22q telomere deletions serendipitously detected by FISH. J Med Genet 35:939–942 (1998).
64.
Qin J, Jia M, Wang L, Lu T, Ruan Y, et al: Association study of SHANK3 gene polymorphisms with autism in Chinese Han population. BMC Med Genet 10:61 (2009).
65.
Riegel M, Baumer A, Wisser J, Acherman J, Schinzel A: Prenatal diagnosis of mosaicism for a del(22)(q13). Prenat Diagn 20:76–79 (2000).
66.
Romain DR, Goldsmith J, Cairney H, Columbano-Green LM, Smythe RH, Parfitt RG: Partial monosomy for chromosome 22 in a patient with del(22)(pter–q13.1::q13.33–qter). J Med Genet 27:588–589 (1990).
67.
Roussignol G, Ango F, Romorini S, Tu JC, Sala C, et al: Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 25:3560–3570 (2005).
68.
Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M: Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 31:115–130 (2001).
69.
Sathyamoorthi S, Morales J, Bermudez J, McBride L, Luquette M, et al: Array analysis and molecular studies of INI1 in an infant with deletion 22q13 (Phelan-McDermid syndrome) and atypical teratoid/rhabdoid tumor. Am J Med Genet A 149A:1067–1069 (2009).
70.
Schmidt H, Kern W, Giese R, Hallschmid M, Enders A: Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. J Med Genet 46:217–222 (2009).
71.
Schroder K, Schuffenhauer S, Seidel H, Bartsch O, Blin N, et al: Deletion mapping by FISH with BACs in patients with partial monosomy 22q13. Hum Genet 102:557–561 (1998).
72.
Slavotinek A, Maher E, Gregory P, Rowlandson P, Huson SM: The phenotypic effects of chromosome rearrangement involving bands 7q21.3 and 22q13.3. J Med Genet 34:857–861 (1997).
73.
Smith DP, Floyd M, Say B: Detection of a familial cryptic translocation by fluorescent in situ hybridisation. J Med Genet 33:84 (1996).
74.
Sutherland G, Couch MA, Iacono T: Health issues for adults with developmental disability. Res Dev Disabil 23:422–445 (2002).
75.
Sykes NH, Toma C, Wilson N, Volpi EV, Sousa I, et al: Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection. Eur J Hum Genet 17:1347–1353 (2009).
76.
Thomas NS, Durkie M, Potts G, Sandford R, Van Zyl B, et al: Parental and chromosomal origins of microdeletion and duplication syndromes involving 7q11.23, 15q11–q13 and 22q11. Eur J Hum Genet 14:831–837 (2006).
77.
Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, et al: Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 106:2029–2034 (2009).
78.
Tufano M, Della Corte C, Cirillo F, Spagnuolo MI, Candusso M, et al: Fulminant autoimmune hepatitis in a girl with 22q13 deletion syndrome: a previously unreported association. Eur J Pediatr 168:225–227 (2009).
79.
Watt JL, Olson IA, Johnston AW, Ross HS, Couzin DA, Stephen GS: A familial pericentric inversion of chromosome 22 with a recombinant subject illustrating a ‘pure’ partial monosomy syndrome. J Med Genet 22:283–287 (1985).
80.
Wilson HL, Wong ACC, Shaw SR, Tse WY, Stapleton GA, et al: Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/ PROSAP2 in the major neurological symptoms. J Med Genet 40:575–584 (2003).
81.
Wilson HL, Crolla JA, Walker D, Artifoni L, Dallapiccola B, et al: Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development. Eur J Hum Genet 16:1301–1310 (2008).
82.
Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, et al: The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med 5:145–150 (2009).
83.
Wong AC, Shkolny D, Dorman A, Willingham D, Roe BA, McDermid HE: Two novel human RAB genes with near identical sequence each map to a telomere-associated region: the subtelomeric region of 22q13.3 and the ancestral telomere band 2q13. Genomics 59:326–334 (1999).
84.
Yong YP, Knight LA, Yong MH, Lam S, Ho LY: Partial monosomy for chromosome 22 in a girl with mental retardation. Singapore Med J 38:85–86 (1997).
85.
Zollino M, Murdolo M, Marangi G, Pecile V, Galasso C, et al: On the nosology and pathogenesis of Wolf-Hirschhorn syndrome: genotype-phenotype correlation analysis of 80 patients and literature review. Am J Med Genet C Semin Med Genet 148C:257–269 (2008).
86.
Zwaigenbaum L, Siegel-Bartelt J, Teshima I, Ho C: Two patients with 22q13.3 deletions have similar facies and developmental patterns. Am J Hum Genet 47:A45 (1990).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.